Table 1.

Demographic and Baseline Clinical Characteristics of Participants^a

Characteristic	Participants, No. (%)b
Male sex	60 (100)
Age, median (IQR), y	34 (28–41)
Interval median (IQR), d
From confirmed HIV-positive test to ART initiation	29 (14–47)
From estimated date of seroconversion to ART initiation	49 (32–93)
From ART initiation to first VL <50 copies/mLc	133 (90–230)
Baseline values, median (IQR)
CD4 T-cell count, cells/μLd	530 (409–663)
CD8 T-cell count, cells/μLd	1037 (837–1318)
CD4/CD8 ratiod	0.5 (0.4–0.8)
VL, log10 copies HIV RNA/mL	5.4 (4.5–6.4)
Method for diagnosing primary HIV infection
Antigen positive (p24 or PCR) but antibody negative	25 (42)
Rising antibody titer	1 (2)
Negative test result within 6 mo of positive result	28 (47)
Recent incidence testing algorithm	6 (10)
Mode of acquisition
MSM	54 (90)
MSW	1 (2)
Unknown/unrecorded	5 (8)
Initial ART regimen
Unknown/unrecorded	3 (5)
Backbone
Tenofovir containing	52 (87)
Abacavir containing	5 (8)
Additional agent(s)
Protease inhibitor	33 (55)
NNRTI	11 (18)
Integrase inhibitor	12 (20)
Protease inhibitor plus integrase inhibitor	1 (2)

Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; MSM, men who have sex with men; MSW, men who have sex with women, NNRTI, nonnucleoside reverse-transcriptase inhibitor; PCR, polymerase chain reaction; VL, viral load.

^aDemographic and baseline clinical characteristics of included participants from the HEATHER cohort.

^bData represent no. (%) of participants unless otherwise identified as median (IQR) values.

^cFifty-nine of 60 individuals were virologically suppressed to <50 copies/mL before 1-year study visit; the remaining individual achieved virological suppression shortly thereafter, at the next VL measurement (Supplementary Figure 1)

^dData available for 59 of 60 individuals.